This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
Catalyst Pharmaceuticals (CPRX) Q2 Earnings Top, Revenues Up
by Zacks Equity Research
Catalyst (CPRX) beat earnings and sales estimate in second-quarter 2022 earnings. Consequently, the stock surges.
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 17.65% and 7.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q2 Earnings on Aug 9: EXEL, BHC & More
by Kinjel Shah
Let us look at four drug and biotech companies, EXEL, BHC, CPRX and AXSM, which are gearing up for their earnings release.
Catalyst Pharmaceuticals (CPRX) Rallies 43% YTD: Here's Why
by Zacks Equity Research
Catalyst's (CPRX) price rallies on the back of the robust performance of its lead drug, Firdapse, approved for treating LEMS in adults. The company is also trying to launch Firdapse in the international markets.
Catalyst (CPRX) Stock Jumps 10%: Will It Continue to Soar?
by Zacks Equity Research
Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Catalyst (CPRX) Settles Patent Dispute Over Sole Marketed Drug
by Zacks Equity Research
Catalyst (CPRX) settles patent litigation disputes related to Firdapse, its LEMS drug. This settlement further strengthens CPRX's intellectual property hold over the drug through 2034.
Catalyst (CPRX) Up 6.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y
by Zacks Equity Research
Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.
Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of -14.29% and 0.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -13.99% and 8.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?